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CHO cells are the workhorses of the biopharmaceutical field with many success stories. However human cell-
based systems might bring important advantages. These can provide production systems resulting in proteins 
with more human-like posttranslational modifications and potentially alleviate the production of difficult-to-
produce molecules. HEK 293 cells are well known and used today for the production of two biopharmaceuticals 
and for viral vectors. The purpose of the present study is to evaluate the potential of this system for its ability to 
produce biopharmaceuticals, benchmarking against CHO cells. 
 
We are currently exploring the possibility to secrete human proteins in CHO cells by systematically addressing 
all the human proteins naturally secreted in the human body. So far, we have covered around half of the human 
secretome (N = 3000) with an overall success rate around 65%. To address the need for a host capable of 
expressing difficult-to-produce proteins, different HEK 293 strains have been investigated for the production of 
30 selected proteins in comparison with CHO cells, revealing a higher success rate in HEK 293 system. This 
expression has been studied in flask system and includes comparative transcriptomics analyses.  
 
To evaluate the potential of HEK 293 cells for the production of biopharmaceuticals, a high cell density perfusion 
process using Alternating Tangential Flow filtration has been developed for the production of EPO. In this 
process, the cells are stably maintained at a density of 80 to 100 x 106 cells/mL while the EPO cell specific 
productivity is comparable to low cell density (e.g. 20 x106 cells/ml) in perfusion mode. The cell metabolism is 
slowed down by lowering the temperature, allowing a reduction of the perfusion rate down to 1 reactor volume 
per day at this high cell concentration. This process has been developed in our new scale-down perfusion 
bioreactor of 200 mL working volume. In this system, the effect of shear stress on the HEK 293 cells resulting 
from their passage in the hollow fibre filter has been characterised by transcriptomics analysis helping to 
decipher why HEK 293 cells are more sensitive than CHO cells and a systematic feeding strategy for perfusion 
has been developed.  
 
The ability to express difficult-to-produce proteins and to achieve very high cell densities with productivity 
comparable to low density processes make HEK 293 cells an attractive system for the production of 
biopharmaceuticals which are challenging for CHO cells. 
 
 
